8 Guangdong-Singapore cooperative projects to settle in CSGKC

Eight Guangzhou-Singapore cooperation projects signed contracts to settle in the China-Singapore Guangzhou Knowledge City (CSGKC) at the 12th Meeting of the Singapore-Guangdong Collaboration Council on Oct 20.

Biosyngen will invest 500 million yuan ($78 million) to build a biomedical production base in the China Nano Valley. The project will integrate R&D, production and sales of cellular immunotherapy and create nearly $10 billion in output value after becoming operational by the end of 2021.

Meanwhile, Ma Kuang will bring international medical resources to its traditional Chinese medicine and rehabilitation hospital in Huangpu. The project will supplement the local public medical treatment system and become a leading brand in South China for chained residential community medical services.

ChemoPower and Hexin Mass Spectrometry will launch a joint R&D center in CSGKC. A memorandum of understanding was signed between the Guangzhou Development District Administrative Committee and Singapore Exchange.

Other projects involve cross-border business registration services, construction of micro power grids, and three-year talent training.